Immunome reported full-year 2025 financial results and provided a business update on March 3, 2026. The global pivotal Phase 3 RINGSIDE trial for varegacestat in patients with progressing desmoid tumors met its primary endpoint, demonstrating an 84% reduction in the risk of disease progression or death (hazard ratio = 0.16, p<0.0001). All key secondary endpoints were also met, including an objective response rate of 56% versus 9% with placebo (p<0.0001). Varegacestat showed a median best change in tumor volume of -83% compared to +11% with placebo in an exploratory analysis. A New Drug Application (NDA) submission to the U.S. FDA for varegacestat is planned for the second quarter of 2026. The Phase 1 clinical trial for IM-1021 (ROR1 ADC) is ongoing, with objective responses observed in B-cell lymphoma patients at multiple dose levels, and initial data expected in 2026. IND clearance was received for IM-3050 (FAP-targeted radiotherapy), with a Phase 1 study planned to initiate in early 2026. Three additional IND submissions for solid tumor-targeted ADC programs (IM-1617, IM-1340, IM-1335) are planned for early, mid, and late-2026, respectively, utilizing Immunome's proprietary HC74 TOP1 inhibitor payload. An underwritten public offering in December 2025 raised $460.5 million in gross proceeds, resulting in net proceeds of $432.4 million. Cash and cash equivalents totaled $653.5 million as of December 31, 2025, extending the projected cash runway into 2028. The net loss for the year ended December 31, 2025, was $212.4 million, an improvement from a net loss of $293.0 million in 2024. Research and development expenses increased to $177.3 million in 2025 from $129.5 million in 2024, while in-process research and development expenses decreased to $10.0 million from $152.3 million.